Pierre Queiroz de Oliveira,Attorney, Pepper Hamilton LLP to Speak at the Knowledge Group's The BPCIA Patent Dance-What Biosimilar Companies Need To Know

Top Quote This event is scheduled for January 10, 2017 from 3:00pm - 5:00pm. End Quote
  • (1888PressRelease) December 29, 2016 - The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Pierre E. Queiroz de Oliveira, Attorney, Pepper Hamilton LLP will speak at the Knowledge Group's webcast entitled: "BPCIA Patent Dance - What Biosimilar Companies Need To Know LIVE Webcast."

    For further details, please visit:
    https://theknowledgegroup.org/event-homepage/?event_id=2114

    About Pierre E. Queiroz de Oliveira
    Pierre Queiroz de Oliveira is an attorney in the Intellectual Property Practice Group of Pepper Hamilton LLP. Dr. Queiroz de Oliveira concentrates his practice on intellectual property transactions and counseling, with a substantial portion of his work directed to patent preparation and prosecution, due diligence and licensing matters. Dr. Queiroz de Oliveira has extensive basic science experience and holds a Ph.D. in molecular pharmacology from the University of Pittsburgh School of Medicine. During his tenure at the University of Pittsburgh, Dr. Queiroz de Oliveira was selected as a Fellow in molecular pharmacology. His scientific and technological experience include pharmacology, pharmaceuticals and drug development, molecular biology, biochemistry and organic chemistry. Dr. Queiroz de Oliveira has been published in a number of peer-reviewed journals and his research has been presented at numerous national meetings. He can be reached at queirozp ( @ ) pepperlaw dot com dot

    About Pepper Hamilton LLP
    Pepper Hamilton LLP is a multi-practice law firm with more than 500 lawyers nationally. The firm provides corporate, litigation and regulatory legal services to leading businesses, governmental entities, nonprofit organizations and individuals throughout the nation and the world.

    Pepper Hamilton LLP's Intellectual Property Department helps its clients protect and commercialize their intellectual property assets while minimizing the risk of liability. They assist companies with the full gamut of intellectual property matters, including patents, copyrights, trademarks, trade secret protection, unfair competition, privacy, and technology-related transactions. They recognize that IP is a vital part of any company's asset portfolio, and, when conflicts arise, they work to efficiently resolve disputes through litigation or alternative methods. As a truly global practice, their IP experience extends beyond the United States. They structure, draft and negotiate agreements between both domestic companies and domestic companies and their foreign counterparts.

    Event Synopsis:
    For about seven years now, the Biologics Price Competition and Innovation Act ("BPCIA") of 2009 has continually facilitated entry of biosimilar products into the market. By allowing submission of an abbreviated Biologics License Application ("aBLA") to an already approved and licensed FDA product, BPCIA aids in making the pioneer and the applicant meet halfway. However, meeting halfway is not as easy as it sounds. There are matters to deal with: agreements and disclosures to be settled down before the commercial marketing of a biosimilar product begins. Patent disputes are among the most debated, and often controversial issues that biosimilar companies are faced with.

    In its second part, BPCIA addresses certain patent resolution issues. Commonly called as the "patent dance", 42 U.S.C. § 262(l) provides the steps and schedule when a reference sponsor product and a biosimilar applicant exchange "confidential information" about the aBLA. Typically, the confidential information disclosed by the applicant is its application and manufacturing trade secrets.

    Indeed, the music hasn't stopped for biosimilar companies, and "patent dance" is still obviously becoming a dance craze for them. Questions remain as to whether or not companies facing the "dance" will minimize the potential for litigation under the BPCIA, and to what extent will this craze bring the industry.

    The Knowledge Group has assembled a panel of key thought leaders to provide the audience with an in-depth analysis of the BPCIA "Patent Dance" and its recent developments. In this two-hour LIVE Webcast, a panel of distinguished professionals and thought leaders will help biosimilar companies understand the important aspects of this significant topic. Speakers will also offer best practices in helping the audience better understand the steps and legal issues brought by the latest litigations.

    About The Knowledge Group/The Knowledge Congress Live Webcast Series
    The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information